10,369 Shares in LifeStance Health Group, Inc. (NASDAQ:LFST) Bought by Townsquare Capital LLC

Townsquare Capital LLC acquired a new position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,369 shares of the company’s stock, valued at approximately $73,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LFST. Principal Financial Group Inc. boosted its position in LifeStance Health Group by 6.1% during the third quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company’s stock worth $28,817,000 after purchasing an additional 235,316 shares in the last quarter. Jennison Associates LLC boosted its position in LifeStance Health Group by 9.5% during the third quarter. Jennison Associates LLC now owns 2,136,942 shares of the company’s stock worth $14,959,000 after purchasing an additional 184,896 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in LifeStance Health Group by 36.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,104,453 shares of the company’s stock worth $7,731,000 after purchasing an additional 297,723 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in LifeStance Health Group by 82.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,016,452 shares of the company’s stock worth $4,991,000 after purchasing an additional 457,930 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in LifeStance Health Group during the second quarter worth $4,326,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

Insider Activity

In other news, Director Robert Bessler sold 75,000 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $7.54, for a total value of $565,500.00. Following the completion of the sale, the director now owns 1,424,447 shares in the company, valued at approximately $10,740,330.38. This trade represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.60% of the company’s stock.

LifeStance Health Group Stock Performance

Shares of NASDAQ:LFST opened at $7.34 on Monday. The firm has a market capitalization of $2.81 billion, a PE ratio of -28.23 and a beta of 1.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.32 and a quick ratio of 1.32. The business has a 50-day moving average of $7.13 and a two-hundred day moving average of $6.28. LifeStance Health Group, Inc. has a 12 month low of $4.64 and a 12 month high of $9.20.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The company had revenue of $312.70 million during the quarter, compared to analyst estimates of $302.25 million. During the same period in the prior year, the firm posted ($0.17) earnings per share. The firm’s revenue was up 18.9% on a year-over-year basis. As a group, research analysts forecast that LifeStance Health Group, Inc. will post -0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

LFST has been the topic of a number of research analyst reports. UBS Group decreased their target price on LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating on the stock in a research report on Thursday, August 15th. Barclays increased their target price on LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.50.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.